Basit öğe kaydını göster

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

dc.contributor.authorTural, Deniz
dc.contributor.authorGautschi, Oliver
dc.contributor.authorZirtiloglu, Alisan
dc.contributor.authorEralp, Yesim
dc.contributor.authorCinkir, Havva Yesil
dc.contributor.authorSezer, Ahmet
dc.contributor.authorERMAN, MUSTAFA
dc.contributor.authorTurna, Hande
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorYildiz, Ibrahim
dc.contributor.authorKaplan, M. Ali
dc.contributor.authorÖZYILKAN, ÖZGÜR
dc.contributor.authorOztop, Ilhan
dc.contributor.authorOlmez, Omer Fatih
dc.contributor.authorAydin, Kubra
dc.contributor.authorAydiner, Adnan
dc.contributor.authorMeydan, Nezih
dc.contributor.authorGrinberg, Roxana Denisa
dc.contributor.authorRoisman, Laila C.
dc.contributor.authorÇABUK, DEVRİM
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorCoskun, Hasan Senol
dc.contributor.authorOkutur, Kerem
dc.contributor.authorKaraoglu, Aziz
dc.contributor.authorDemirkazik, Ahmet
dc.contributor.authorYazilitas, Dogan
dc.contributor.authorBeypinar, Ismail
dc.contributor.authorSenler, Filiz Cay
dc.contributor.authorNg, Terry L.
dc.contributor.authorCamidge, David Ross
dc.contributor.authorDudnik, Elizabeth
dc.contributor.authorReguart, Noemi
dc.contributor.authorMazieres, Julien
dc.contributor.authorPeled, Nir
dc.contributor.authorGillis, Roni
dc.contributor.authorKILIÇKAP, SAADETTİN
dc.contributor.authorFroesch, Patrizia
dc.contributor.authorOrlov, Sergei
dc.contributor.authorFilippova, Elena
dc.contributor.authorDemirci, Umut
dc.contributor.authorChristopoulos, Petros
dc.contributor.authorÇİÇİN, İRFAN
dc.contributor.authorBasal, Fatma Bugdayci
dc.contributor.authorYilmaz, Cengiz
dc.contributor.authorFedor, Moiseenko
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorPaydas, Semra
dc.date.accessioned2021-03-03T07:52:38Z
dc.date.available2021-03-03T07:52:38Z
dc.identifier.citationPeled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., Demirci U., Christopoulos P., ÇİÇİN İ., Basal F. B. , et al., "GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients", LUNG CANCER, cilt.148, ss.48-54, 2020
dc.identifier.issn0169-5002
dc.identifier.othervv_1032021
dc.identifier.otherav_1467efc6-fcdf-43c6-a061-5b18428ff9fd
dc.identifier.urihttp://hdl.handle.net/20.500.12627/19120
dc.identifier.urihttps://doi.org/10.1016/j.lungcan.2020.07.022
dc.description.abstractLorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we present the largest real-world data of NSCLC patients harboring ALK/ROS1 rearrangements treated with lorlatinib.
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectSOLUNUM SİSTEMİ
dc.subjectOnkoloji
dc.subjectİç Hastalıkları
dc.subjectGöğüs Hastalıkları ve Allerji
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleGLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
dc.typeMakale
dc.relation.journalLUNG CANCER
dc.contributor.departmentRabin Medical Center , ,
dc.identifier.volume148
dc.identifier.startpage48
dc.identifier.endpage54
dc.contributor.firstauthorID2288122


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster